Botanix Pharmaceuticals Limited

For the first half of fiscal 2026, Botanix reported total revenue of $16.5 million, up from $346,000 in the prior corresponding period. U.S. Sofdra revenue was $16.2 million, and total prescriptions shipped increased 171% to 45,800, up from 16,800 in the second half of fiscal 2025. Materials and related expenses were $6 million, direct operating expenses were $36.6 million, adjusted EBITDA loss was $26.1 million, and cash and equivalents ended at $31.6 million. Management said Sofdra generated almost $100 million in gross revenue and $21.2 million in net revenue over its first 11 months of launch. For the balance-sheet and funding outlook, Botanix said it received firm commitments for a $45 million capital raise, with $14.9 million received to date and the balance subject to shareholder approval on April 1, 2026. The company said the raise will fund API and manufacturing purchases, alternate supplier setup, advertising and marketing, operating expenses, working capital, and transaction costs.

CEO Howie McKibbon framed the quarter as proof that Sofdra and the company’s commercial platform are working better than expected. He emphasized the product’s addressable market, saying primary axillary hyperhidrosis affects over 10 million patients in the U.S., and highlighted the durability of Sofdra’s IP runway to 2040. He was optimistic about adding more products to the platform, saying the infrastructure is scalable and could make new assets immediately accretive without major added development cost.

CFO Chris Lesovitz focused on the financial shape of a scaling launch business. He cited $16.5 million in total revenue, $6 million in materials and related expenses, $36.6 million in direct operating expenses, and a $26.1 million adjusted EBITDA loss, alongside $31.6 million in cash and equivalents at period end. He said sales and marketing rose to $24.7 million and employee costs to $7 million as the company expanded its U.S. commercial footprint, while G&A stayed relatively controlled at $3.2 million.

In Q&A, management spent significant time on the API supply situation. Howie McKibbon said the current API is sourced from a sole supplier because Sofdra is a new chemical entity and the company is now working to qualify an alternate supplier; he said that takes time for technology transfer, validation, and FDA inspection, but could cut COGS by 25% to 40%. They also clarified that the company is not committed to buying API three times per year going forward: the near-term purchases are the March and April 2026 and January 2027 obligations, while 2028 through 2030 require only one purchase per year, at any time during each year. On the raise, Chris said the $45 million package is intended mainly for API/manufacturing, supplier setup, marketing, working capital, and transaction costs.